Financial Results | TNF Pharmaceuticals 2025 Q1 Net Loss USD 1.12 Million

TNF Pharmaceuticals(TNFA) posted the Q1 of its 2025 financial results on 5/15/2025, reporting net loss of USD 1.12 million in the first quarter, narrowing 88.52% from USD -9.80 million year over year. The EPS is USD -0.36 in the frist quater, compare with USD -5.14 last period.

[Detailed Data]

Million USD	Q1 2025	Q4 2024	Q3 2024	Q4 2024
Total Operating Expenses	2.41	2.04	1.66	2.04
Operating Income	-2.41	-2.04	-1.66	-2.04
Net Income	-1.12	-2.06	-1.93	-2.06
Net Income Attributable to Common Shareholders	-1.94	-3.14	-2.68	-3.14
EPS(USD)	-0.36	-0.9323	-1.11	-0.9323

[Company Profile]
TNF Pharmaceuticals, Inc., incorporated under the laws of the State of New Jersey on March 9, 1989 under the name A.R.C. Enterprises, Inc. On July 22, 2024, the Company changed its incorporation to the State of Delaware. The company is a clinical stage pharmaceutical company committed to extending healthy lifespan. TNF is focused on developing and commercializing two therapeutic platforms based on well-defined therapeutic targets, Isomyosamine and Supera-CBD.